11th CIMT Annual Meeting - Advancing Targeted Therapies

The Association for Cancer Immunotherapy (CIMT) is an initiative led by leading European immunologists and clinicians devoted to the advancement of cancer immunotherapies. Mainz, the scenic 2000 year old city of J. Gutenberg, located on the Rhine River close to Frankfurt, has hosted the CIMT meetings since 2002. With more than 600 regular participants, these meetings have become the most prominent international expert gatherings in Europe focusing on research in cancer immunotherapy, and the 2013 CIMT meeting will continue to address the most recent developments, challenges and successes in the field. In this year`s meeting we will follow the progress of cancer immunotherapy and focus on the advancement of targeted therapies

CIMT2013 calling for abstract submissions in the sub-specialties of:
Cellular Therapy, Therapeutic Vaccination, Therapeutic Antibodies, Immunomonitoring, New Targets, Cancer Biology, Immunotherapy, Immune Suppression, Innate Immunity

+ show speakers and program
Tak W. Mak, Ontario Cancer Institute, Toronto, Canada
Vincenzo Bronte, University of Verona
Ira Mellmann, Genentech, San Francisco, USA
Jill Slansky, University of Colorado School of Medicine, USA
Suzanne Ostrand-Rosenberg, UMBC, Baltimore, USA
Holden T. Maecker, Stanford School of Medicine, Stanford, USA
Hans-Georg Rammensee, University of Tübingen, Tübingen, Germany
Axel Hoos, Glaxo Smith Kline Pharmaceuticals, Collegeville, USA
Ulrich Kalinke, Twincore, Hanover, Germany
George C. Prendergast, Lankenau Institute for Medical Research, Wynnewood, PA
Dolores Schendel, Helmholtz Zentrum, Munich, Germany
Philipp Beckhove, DKFZ, Heidelberg, Germany
Alberto Mantovani, Istituto Clinico Humanitas, Milan, Italy
Samir Khleif, Georgia Health Sciences University, Augusta, USA
Eva-Maria Jahn, Paul-Ehrlich Institut
Steffen Walter, immatics biotechnologies

14 May - 16 May 2013

meeting website